Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor,

[Farooqji]

Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease

BIIB122/DNL151 demonstrated a safety profile supporting continued development in patients with Parkinson’s disease

Data support once daily oral dosing with BIIB122/DNL151

Denali and Biogen plan to advance BIIB122/DNL151 into late-stage development in patients with Parkinson’s disease by year-end 2021

denalitherapeutics.com/inve...

[Parkinsonjisung]

Promising. Can't say I understand what the biomarkers mean though, haha

[sharoncrayn]

This is a report on their LRRK-2 (gene mutation) drug BIIB122/DNL151 using biomarkers to assess results on primarily healthy volunteers without PD..

Positive results were seen in "biomarkers"( ...a measurable substance (sP935) in a blood sample whose presence is indicative of some disease such as PD mutated LRRK-2,) "the magnitude of reduction required for normalization of increased LRRK2 kinase activity observed in Parkinson’s patients with kinase activating LRRK2 mutations."

Will these results translate to PD patients who are actually LRRK-2? Long way to go.

Sharon

[Hidden]

healthunlocked.com/cure-par...